Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M. Tolaney, Andrew Wardley, Stefania Zambelli, John Hilton, Tiffany A. Troso-Sandoval, Francesco Ricci, Seock‐Ah Im, Sung‐Bae Kim, Stephen Johnston, Arlene Chan, Shom Goel, Kristen Catron, Sonya C. Chapman, Gregory L. Price, Zhengyu Yang, M. Corona Gainford, Fabrice André